enGene (NASDAQ:ENGN) Downgraded by Wall Street Zen to Sell

Wall Street Zen cut shares of enGene (NASDAQ:ENGN) from a hold rating to a sell rating in a report released on Saturday.

Other analysts also recently issued reports about the company. Citigroup restated a “market outperform” rating on shares of enGene in a report on Monday, January 5th. WBB Securities began coverage on enGene in a report on Monday, April 13th. They issued a “buy” rating and a $21.50 price objective for the company. Jefferies Financial Group began coverage on enGene in a report on Friday, January 30th. They issued a “buy” rating and a $28.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of enGene in a report on Wednesday, April 8th. Finally, Guggenheim reiterated a “buy” rating on shares of enGene in a report on Tuesday, March 10th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, enGene has a consensus rating of “Moderate Buy” and an average price target of $22.69.

enGene Stock Performance

NASDAQ ENGN opened at $8.07 on Friday. The company has a market capitalization of $540.61 million, a price-to-earnings ratio of -3.59 and a beta of -0.06. enGene has a twelve month low of $2.65 and a twelve month high of $12.25. The stock has a fifty day simple moving average of $8.21 and a 200 day simple moving average of $8.37. The company has a quick ratio of 11.75, a current ratio of 11.75 and a debt-to-equity ratio of 0.09.

enGene (NASDAQ:ENGN) last posted its quarterly earnings data on Monday, March 9th. The company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.11. Sell-side analysts expect that enGene will post -1.56 EPS for the current year.

Institutional Trading of enGene

Large investors have recently bought and sold shares of the business. Cresset Asset Management LLC acquired a new stake in shares of enGene in the 2nd quarter valued at about $36,000. Paloma Partners Management Co acquired a new stake in shares of enGene in the 2nd quarter valued at about $38,000. PFS Partners LLC acquired a new stake in shares of enGene in the 3rd quarter valued at about $61,000. Raymond James Financial Inc. grew its stake in shares of enGene by 383.6% in the 3rd quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock valued at $68,000 after buying an additional 7,932 shares during the period. Finally, Hudson Bay Capital Management LP acquired a new stake in shares of enGene in the 3rd quarter valued at about $76,000. 64.16% of the stock is currently owned by institutional investors and hedge funds.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.